Abstract
Protein tyrosine phosphatase 1B (PTP1B) is a negative regulator of the insulin signalling pathway. It has been demonstrated that PTP1B deletion protects against the development of obesity and Type 2 Diabetes, mainly through its action on peripheral tissues. However, little attention has been paid to the role of PTP1B in β-cells. Therefore, our aim was to study the role of PTP1B in pancreatic β-cells. Silencing of PTP1B expression in a pancreatic β-cell line (MIN6 cells) reveals the significance of this endoplasmic reticulum bound phosphatase in the regulation of cell proliferation and apoptosis. Furthermore, the ablation of PTP1B is able to regulate key proteins involved in the proliferation and/or apoptosis pathways, such as STAT3, AKT, ERK1/2 and p53 in isolated islets from PTP1B knockout (PTP1B (-)/(-)) mice. Morphometric analysis of pancreatic islets from PTP1B (-)/(-) mice showed a higher β-cell area, concomitantly with higher β-cell proliferation and a lower β-cell apoptosis when compared to islets from their respective wild type (WT) littermates. At a functional level, isolated islets from 8 weeks old PTP1B (-)/(-) mice exhibit enhanced glucose-stimulated insulin secretion. Moreover, PTP1B (-)/(-) mice were able to partially reverse streptozotocin-induced β-cell loss. Together, our data highlight for the first time the involvement of PTP1B in β-cell physiology, reinforcing the potential of this phosphatase as a therapeutical target for the treatment of β-cell failure, a central aspect in the pathogenesis of Type 2 Diabetes.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Apoptosis
-
Cell Count
-
Cell Line
-
Cell Proliferation
-
Diabetes Mellitus, Experimental / chemically induced
-
Diabetes Mellitus, Experimental / enzymology
-
Diabetes Mellitus, Experimental / genetics*
-
Diabetes Mellitus, Experimental / pathology
-
Endoplasmic Reticulum / chemistry
-
Endoplasmic Reticulum / enzymology
-
Gene Expression Regulation*
-
Glucose / metabolism
-
Glucose / pharmacology
-
Insulin / metabolism
-
Insulin Secretion
-
Insulin-Secreting Cells / drug effects
-
Insulin-Secreting Cells / enzymology*
-
Insulin-Secreting Cells / pathology
-
Male
-
Mice
-
Mice, Knockout
-
Mitogen-Activated Protein Kinase 1 / genetics
-
Mitogen-Activated Protein Kinase 1 / metabolism
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1 / antagonists & inhibitors
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1 / genetics*
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1 / metabolism
-
Proto-Oncogene Proteins c-akt / genetics
-
Proto-Oncogene Proteins c-akt / metabolism
-
RNA, Small Interfering / genetics
-
RNA, Small Interfering / metabolism
-
STAT3 Transcription Factor / genetics
-
STAT3 Transcription Factor / metabolism
-
Signal Transduction
-
Streptozocin
-
Tumor Suppressor Protein p53 / genetics
-
Tumor Suppressor Protein p53 / metabolism
Substances
-
Insulin
-
RNA, Small Interfering
-
STAT3 Transcription Factor
-
Stat3 protein, mouse
-
Tumor Suppressor Protein p53
-
Streptozocin
-
Proto-Oncogene Proteins c-akt
-
Mitogen-Activated Protein Kinase 1
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1
-
Ptpn1 protein, mouse
-
Glucose
Grants and funding
This work was sponsored by the Spanish Ministry of Science and Innovation (MICINN) under the grant agreement number SAF 2010-19527 (RG), the Government of Catalonia under the grant agreement number 2009 SGR 1426 (RG), and grant BFU2011-24679 (PMG-R). PGR is a recipient of a Ramon y Cajal contract (RYC-2009-05158) from MICINN. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.